FORM	4
------	---

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

П

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB 3235-0287 Number: December 31, 2014 Estimated average burden hours per response 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Wicki Andreas			2. Issuer Name and Ticker or Trading Symbol Pacira Pharmaceuticals, Inc. [PCRX]	5. Relationship of Reporting Person(s) to Issuer				
	(Last) (First) (Middle)		3. Date of Earliest Transaction (Month/Day/Year) 09/11/2013	(Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)				
(Street) GRAND CAYMAN (City)	E9 (State)	00000 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 				

	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Instr. 8)		4. Secur Acquired Dispose (Instr. 3,	d (A) d of	or (D)	5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)	or Indirect (I) (Instr. 4)	(Instr. 4)	
Common Stock	09/11/2013		x		37,192	Α	\$ 2.69	1,668,136	I	See footnote. ⁽¹⁾	
Common Stock	09/11/2013		S ⁽²⁾		2,686	D	\$ 37.25	1,665,450	I	See footnote. ⁽¹⁾	
Common Stock	09/11/2013		x		41,841	Α	\$ 13.44	1,707,291	I	See footnote. ⁽¹⁾	
Common Stock	09/11/2013		S ⁽³⁾		15,097	D	\$ 37.25	1,692,194	I	See foootnote.	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Instr. 8)		on Number of Derivative				Amount of Underlying		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warrant (right to buy)	\$ 2.69	09/11/2013		x			37,192	01/22/2009	01/21/2014	Common Stock	37,192	\$0	0	I	See footnote. (1)
Warrant (right to buy)	\$ 13.44	09/11/2013		x			41,841	12/29/2010	12/29/2017	Common Stock	41,841	\$0	0	I	See footnote. (1)

Explanation of Responses:

1. The board of directors of HBM Healthcare Investments (Cayman) Ltd. ("HBM") has sole voting and investment power with respect to the securities held by such entity and acts by majority vote. The reporting person does not have sole voting or investment power over the securities held by HBM. However, the reporting person may be deemed to have beneficial ownership of these securities by virtue of his membership on the board of directors of HBM. The reporting person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest herein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose of Section 16 of the Exchange Act, or for any other purpose.

2. On September 11, 2013, HBM exercised a warrant to purchase 37,192 shares of the Issuer's common stock for \$2.69 a share. HBM paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 2,686 of the warrant shares to pay the exercise price and issuing to HBM the remaining 34,506 shares. The Issuer also paid \$7.02 to HBM in lieu of a fractional share.

3. On September 11, 2013, HBM exercised a warrant to purchase 41,841 shares of the Issuer's common stock for \$13,44 a share. HBM paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 15,097 of the warrant shares to pay the exercise price and issuing to HBM the remaining 26,744 shares. The Issuer also paid \$20.21 to HBM in lieu of a fractional share.

> /s/ Mehdi Khodadad (Attorney-in-Fact) ** Signature of Reporting Date Person

09/12/2013

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.